Redemplo is a drug owned by Arrowhead Pharmaceuticals Inc. It is protected by 5 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 10, 2038. Details of Redemplo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US12365899 | NA |
Sep, 2038
(12 years from now) | Active |
| US11214801 | NA |
Sep, 2038
(12 years from now) | Active |
| US10597657 | NA |
Sep, 2038
(12 years from now) | Active |
| US10294474 | NA |
Mar, 2037
(11 years from now) | Active |
| US11174481 | NA |
Mar, 2037
(11 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Redemplo is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Redemplo's family patents as well as insights into
ongoing legal events
on those patents.
Redemplo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Redemplo's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 10, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Redemplo Generics:
There are no approved generic versions for Redemplo as of now.
About Redemplo
Redemplo is a drug owned by Arrowhead Pharmaceuticals Inc. Redemplo uses Plozasiran Sodium as an active ingredient. Redemplo was launched by Arrowhead in 2025.
Approval Date:
Redemplo was approved by FDA for market use on 18 November, 2025.
Active Ingredient:
Redemplo uses Plozasiran Sodium as the active ingredient. Check out other Drugs and Companies using Plozasiran Sodium ingredient
Dosage:
Redemplo is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) | SOLUTION | Prescription | SUBCUTANEOUS |